Flonase is actually a medication called fluticasone propionate. Long before it became popular for treating stuffy nose, it was used to treat Crohn's disease (a condition causing irritation that "skips" along the digestive tract), ulcerative colitis (a similar condition that doesn't "skip" but causes continuous areas of inflammation), another digestive tract problem called esinophilic esophagitis, nasal polyps, and asthma. Like Nasacort, Flonase is a potent steroid drug that can rapidly reduce swelling and inflammation of mucosal linings of the nose and throat. Unlike Nasacort, Flonase is relatively specific and doesn't have the same potential for systemic side effects, such as:
Budesonide has a systemic clearance of approximately L/min in 4-6 years old asthmatic children. Per kg body weight children have a clearance which is approximately 50% greater than in adults. The terminal half-life of budesonide after inhalation is approximately hours in asthmatic children. This is about the same as in healthy adults. The Area Under Curve (AUC) after administration of 256 micrograms budesonide from RHINOCORT AQUA is nmol*h/L in children, indicating a higher systemic glucocorticosteroid exposure in children than in adults. At clinically recommended doses, the pharmacokinetics of budesonide are dose-proportional and plasma exposure is correlated to the weight of the patient. Therefore this should be taken into account when establishing paediatric doses.